The intellectual foundation of this shift was laid by Academician Daiming Fan, chairman of the China Anti-Cancer Association, who proposed holistic integrative medicine as a medical methodology rather than a simple aggregation of therapies. The framework rests on three hierarchical goals: anticancer treatment as the foundation, tumor control as the intermediate level, and patient-centric care as the overarching orientation. Since 2025, the China Anti-Cancer Association’s Frontiers Broadcast platform has curated original Chinese studies from top-tier journals, providing the empirical backbone for the new review. Within this structure, the authors identify a three-level progressive transformation: from single molecular targets to system-level networks, from single-modality treatment to temporally coordinated multidisciplinary care, and from disease-oriented management to whole-course care spanning prevention, screening, diagnosis, treatment, and rehabilitation.

At the molecular level, the review documents a striking move from static, single-event biology toward dynamic processes and cross-system interactions. A team led by Zhu Weiguo at Shenzhen University reported in Nature that deamidation of histone H1 at asparagine residues 76 and 77 triggers a cascade that promotes acetylation at the adjacent H1K75 site, driving chromatin relaxation and recruiting DNA repair factors—recasting DNA damage response as a dynamic chromatin process rather than a static mutational event. At Sun Yat-sen University Cancer Center, the teams of Kang Tiebang and Wu Yuanzhong identified through CRISPR–Cas9 screening that ASB7 acts as a key negative regulator of H3K9me3; ASB7 amplification induces genomic instability and sensitizes tumors to PARP inhibitors, pointing to a new biomarker-defined beneficiary population. Xu Yanhui’s group at Fudan University reconstructed the full dynamic trajectory of human RNA polymerase III transcription initiation, while Yu Yang’s team at the Chinese Academy of Medical Sciences showed that distinct fusion genes, MN1–BEND2 and MN1–CXXC5, converge on the same CGTT DNA motif to initiate astrocytoma—a concept the authors call convergent oncogenesis.

Equally consequential is the reframing of tumors as ecological systems that span organs. Zhang Zemin’s team at Peking University used single-cell transcriptomic and T cell receptor sequencing of 343 surgical specimens to define five tumor immune microenvironment subtypes in non-small cell lung cancer treated with neoadjuvant anti-PD-1 therapy, linking NK cell–enriched, B cell–enriched, and effector T cell–enriched profiles to high response rates. Ji Tong and Sun Yunfan at Fudan University’s Zhongshan Hospital revealed in Cell that tumor cells activate sensory neurons through an ATF4–SLIT2 axis, remodeling immune landscapes in tumor-draining lymph nodes to escape surveillance—an inter-organ neuroimmune circuit that fuses oncology, neuroscience, and immunology. Kuang Dongming’s group showed that glucose deprivation reshapes the pulmonary immune microenvironment through exosomal TRAIL to create a pre-metastatic niche, a process reversible by TIGIT blockade, directly connecting metabolism to immune ecology.

Methodologically, Chinese teams are dissolving disciplinary boundaries. Zhao Yongxiang’s group at Guangxi Medical University engineered an oncolytic Newcastle disease virus, NDV-GT, carrying the porcine α1,3-galactosyltransferase gene; infected tumor cells display the α-Gal antigen and provoke a hyperacute rejection–like immune response borrowed from transplant immunology. Liu Chenli at the Shenzhen Institute of Advanced Technology reprogrammed bacteria with genetic circuits to selectively proliferate in tumors and revitalize antitumor immunity, while Han Shuo’s team developed the PATCH platform, using light- or ultrasound-activated nanozymes to catalyze proximity labeling of tumor antigens and amplify CD8-positive T cell responses. Tan Weihong’s team at Zhejiang Cancer Hospital introduced SPARK-seq in Science, a multimodal platform combining CRISPR perturbation with single-cell multi-omics to map aptamer–target interactions at high throughput.

The clinical tier of the paradigm shift is perhaps most vivid in nasopharyngeal carcinoma, a tumor with particular relevance to southern China. Ma Jun’s group at Sun Yat-sen University Cancer Center demonstrated in CA: A Cancer Journal for Clinicians that reduced-volume radiotherapy after induction chemotherapy does not increase recurrence while significantly cutting toxicity. The DIPPER trial in JAMA showed that adjuvant camrelizumab raised three-year disease-free survival to 87 percent in high-risk locally advanced disease, and the DIAMOND trial established toripalimab-based chemoradiotherapy that maintains efficacy while reducing cisplatin-associated toxicity—challenging the assumption that efficacy and toxicity trade off in a zero-sum relationship. In The Lancet, Zhang Li’s team reported that iza-bren, an EGFR×HER3 bispecific antibody-drug conjugate, doubled the benefit of standard chemotherapy in heavily pretreated recurrent or metastatic disease.

In lung cancer, the HARMONi-2 trial led by Zhou Caicun showed that ivonescimab, the first PD-1/VEGF bispecific antibody, extended median progression-free survival to 11.1 months versus pembrolizumab, heralding what the review calls an immunotherapy 2.0 era. The HARMONi-6 trial extended this benefit to squamous carcinoma with a grade three-or-higher hemorrhage rate of only 1.9 percent, while Zhang Li’s group showed that the Trop-2 antibody-drug conjugate sacituzumab tirumotecan outperformed docetaxel in EGFR-mutant disease, confirmed in a New England Journal of Medicine phase III trial after EGFR-TKI resistance. Chen Haiquan’s team demonstrated that mediastinal lymph node dissection can be safely omitted in ground-glass opacity–dominant early lung cancer, and the JAMA-published Aifei Plan led by Jianxing He and Wenhua Liang extended low-dose CT screening from high-risk groups to the general population, shifting intervention to the preclinical stage.

Gastrointestinal, breast, gynecologic, and hematologic oncology tell the same story of integration and de-escalation. The TaLaR trial validated transanal total mesorectal excision for low rectal cancer, the REAL trial showed robotic surgery improves long-term outcomes over laparoscopy, and the NEOTERIC trial achieved a 35.7 percent pathological complete response rate with dual immunotherapy after neoadjuvant chemoradiotherapy in locally advanced rectal cancer. Lin Shen’s group reported the world’s first randomized trial of a Claudin 18.2-targeted CAR-T therapy, satri-cel, in advanced gastric cancer, alongside the GEMSTONE-303 trial of sugemalimab plus chemotherapy. In breast cancer, the FASCINATE-N trial showed that the HER2-targeted antibody-drug conjugate SHR-A1811 matched conventional quadruple neoadjuvant therapy in pathological complete response with better safety, and a BMJ trial found that oral mecobalamin halves the risk of severe capecitabine-induced hand–foot syndrome—a drug-repurposing strategy squarely aimed at quality of life. The PHENIX trial in NEJM showed pelvic lymphadenectomy can be omitted in sentinel-node-negative cervical cancer, and CD19 CAR-T therapy was extended for the first time to refractory autoimmune hemolytic anemia, while Wensheng Wei’s team engineered a glycan shield enabling off-the-shelf allogeneic CAR-T cells.

The review’s system-level analysis extends the framework from individual patients to population health. A nationwide Lancet cohort led by Xin Ni reported an overall five-year survival of 77.2 percent among Chinese children and adolescents with cancer, surpassing the World Health Organization’s 60 percent target, yet revealed persistent socioeconomic disparities that demand tiered allocation of healthcare resources. A CA: A Cancer Journal for Clinicians analysis projected global childhood cancer trends to 2050, underscoring health inequities between high- and low-HDI regions. Supportive care studies, including a BMJ network meta-analysis of cardiovascular toxicity from EGFR tyrosine kinase inhibitors and the PROFIT trial of HR20013 for preventing chemotherapy-induced nausea and vomiting, embody the patient-centered principle of treating the person, not merely the tumor.

The authors are candid about the challenges ahead. The boundaries of integration remain ill-defined, risking either decision paralysis or a relapse into reductionism; tools to quantify experiential judgment and patient-reported outcomes are lacking; and medical education and hospital structures remain discipline-oriented. Their proposed roadmap calls for quantitative integration through a composite integration score spanning molecular, clinical-temporal, and whole-cycle dimensions; artificial intelligence–enabled decision support with interpretability and dynamic learning; expansion from oncology to other chronic diseases; and international dissemination of the Chinese experience. The transformation, they conclude, is not a repudiation of reductionist achievement but its dialectical advancement—reductionism supplies depth, holistic integrative medicine supplies breadth, and together they mark a decisive step from treating disease toward caring for the person.

Subject of Research: Evolution of cancer research paradigms in China under the holistic integrative medicine framework

Article Title: The evolution of research paradigms in cancer research in China within the framework of holistic integrative medicine

Article References: Bai, X., & Yang, Z. (2026). The evolution of research paradigms in cancer research in China within the framework of holistic integrative medicine. Holistic Integrative Oncology, 5(1), Article 75. https://doi.org/10.1007/s44178-026-00299-0

Image Credits: AI Generated

DOI: 10.1007/s44178-026-00299-0

Keywords: holistic integrative medicine, cancer research in China, systems thinking, tumor microenvironment, immunotherapy, antibody-drug conjugates, CAR-T cell therapy, patient-centered care, paradigm shift, oncology, whole-course cancer management, multidisciplinary therapy